. Département-d'oncologie-médicale, Institut Paoli-Calmettes (IPC)

. Département-d'oncologie-médicale,

A. Université,

. Biostatistiques, Département de la Recherche Clinique et de l'Innovation (DRCI), Institut Paoli-Calmettes

C. Département-de and . Oncologique, Institut Paoli-Calmettes

. Département-de-radiothérapie, Institut Paoli-Calmettes

D. Biopathologie and . De, Biologie du Cancer Institut Paoli-Calmettes

, Institut Paoli-Calmettes, Marseille, F-13273, France. 10. Centre d'Investigations Cliniques en Biothérapies, Inserm CBT-1409, p.13009

S. Dawood, S. D. Merajver, and P. Viens, International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, 2011.

A. Monneur, F. Bertucci, P. Viens, and A. Gonçalves,

, Bull. Cancer (Paris), 2014.

N. M. Rueth, H. Y. Lin, and I. Bedrosian, Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.32, pp.2018-2024, 2014.

E. Frei, B. A. Teicher, and S. A. Holden, Preclinical studies and clinical correlation of the effect of alkylating dose, Cancer Res, vol.48, issue.22, pp.6417-6423, 1988.

E. Frei and G. P. Canellos, Dose: a critical factor in cancer chemotherapy, Am. J. Med, vol.69, issue.4, pp.585-594, 1980.

D. Adkins, R. Brown, and K. Trinkaus, Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.17, issue.7, pp.2006-2014, 1999.

P. Viens, F. Penault-llorca, and J. Jacquemier, High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome, Bone Marrow Transplant, vol.21, issue.3, pp.249-254, 1998.

F. Bertucci, C. Tarpin, C. , and E. , Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment, Bone Marrow Transplant, vol.33, issue.9, pp.913-920, 2004.

G. Somlo, P. Frankel, and W. Chow, Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.22, issue.10, pp.1839-1848, 2004.

P. Viens, T. Palangié, and M. Janvier, First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), Br. J. Cancer, vol.81, issue.3, pp.449-456, 1999.

A. Gonçalves, J. Pierga, and J. Ferrero, UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, 2015.

T. Palangie, P. Viens, and H. Roche, Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977-1987 and two consecutive French multicenter trials Pegase 02 (1995-96) and Pegase 05 (1997-99), ASCO Meet. Abstr, vol.22, p.848, 2004.

M. Martino, A. Bottini, and G. Rosti, Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients, Expert Opin. Biol. Ther, vol.12, issue.11, pp.1505-1515, 2012.

D. A. Berry, N. T. Ueno, and M. M. Johnson, High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.29, issue.24, pp.3214-3223, 2011.

E. Von-elm, D. G. Altman, and M. Egger, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies, PLoS Med, 2007.

K. W. Hance, W. F. Anderson, and S. S. Devesa, Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute, J. Natl. Cancer Inst, vol.97, issue.13, pp.966-975, 2005.

H. Masuda, T. M. Brewer, and D. D. Liu, Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, vol.25, issue.2, pp.384-391, 2014.

L. Gianni, W. Eiermann, and V. Semiglazov, Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet Lond. Engl, vol.375, issue.9712, pp.377-384, 2010.

J. Pierga, T. Petit, and T. Delozier, Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study, Lancet Oncol, vol.13, issue.4, pp.375-384, 2012.

K. Kast, T. Link, and K. Friedrich, Impact of breast cancer subtypes and patterns of metastasis on outcome, Breast Cancer Res. Treat, vol.150, issue.3, pp.621-629, 2015.

J. Qiu, X. Xue, and C. Hu, Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer, J. Cancer, vol.7, issue.2, pp.167-173, 2016.

O. Gluz, K. Mengele, and M. Schmitt, Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, issue.36, pp.6144-6151, 2009.

R. Diallo-danebrock, E. Ting, and O. Gluz, Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy

, Verhandlungen Dtsch. Ges. Für Pathol, vol.91, pp.187-196, 2007.

D. A. Berry, N. T. Ueno, and M. M. Johnson, High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.29, issue.24, pp.3224-3231, 2011.

L. Gianni, T. Pienkowski, and Y. Im, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, vol.13, issue.1, pp.25-32, 2012.

F. Bertucci, P. Finetti, D. Birnbaum, and P. Viens, Gene expression profiling of inflammatory breast cancer, Cancer, vol.116, pp.2783-2793, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01612154

F. Bertucci, N. T. Ueno, and P. Finetti, Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, 2014.